China SXT Pharmaceuticals (NASDAQ:SXTC) Upgraded at Wall Street Zen

Posted by Dante Gardener on Feb 10th, 2026

Wall Street Zen upgraded shares of China SXT Pharmaceuticals (NASDAQ:SXTC – Free Report) to a sell rating in a research report sent to investors on Saturday.

China SXT Pharmaceuticals Trading Down 7.7%

Shares of China SXT Pharmaceuticals stock opened at $2.77 on Friday. The business’s fifty day simple moving average is $132.39 and its 200 day simple moving average is $195.15. China SXT Pharmaceuticals has a 12 month low of $2.34 and a 12 month high of $1,176.00.

China SXT Pharmaceuticals (NASDAQ:SXTC – Get Free Report) last announced its quarterly earnings data on Wednesday, December 31st. The company reported ($4.50) earnings per share (EPS) for the quarter. The business had revenue of $0.31 million during the quarter.

Institutional Investors Weigh In On China SXT Pharmaceuticals

A hedge fund recently raised its stake in China SXT Pharmaceuticals stock. Virtu Financial LLC raised its position in shares of China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC – Free Report) by 107.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 28,983 shares of the company’s stock after purchasing an additional 15,013 shares during the period. Virtu Financial LLC’s holdings in China SXT Pharmaceuticals were worth $46,000 as of its most recent filing with the Securities and Exchange Commission. 5.02% of the stock is currently owned by institutional investors and hedge funds.

About China SXT Pharmaceuticals

(Get Free Report)

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.